Displaying drugs 13926 - 13950 of 14706 in total
KER-047
KER-047 is under investigation in clinical trial NCT05927012 (A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).).
Investigational
Matched Description: … KER-047 is under investigation in clinical trial NCT05927012 (A Study to Evaluate the Safety and Preliminary …
3-Mercuri-4-Aminobenzenesulfonamide
Experimental
Triazolopyridine
Experimental
(Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide
(Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide is a solid. This compound belongs to the phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group. This drug targets the protein S100B.
Experimental
BX-528
Experimental
CAN-508
Experimental
N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide
Experimental
p-Fluorofentanyl
p-Fluorofentanyl is an opioid analgesic being an analogue of fentanyl developed by Janssen Pharmaceutica in the 1960s. p-Fluorofentanyl was sold briefly on the US black market in the early 1980s, before the introduction of the Federal Analog Act which for the first time attempted to control entire families of drugs...
Illicit
Methylbenactyzium
Experimental
Poloxalene
Ethylene oxide/propylene oxide copolymer is used as a food additive. It belongs to the family of Epoxides. These are compounds containing a cyclic ether with three ring atoms (one oxygen and two carbon atoms).
Investigational
Vet approved
Matched Description: … These are compounds containing a cyclic ether with three ring atoms (one oxygen and two carbon atoms) …
NM-702
Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis obliterans.
M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. In Japan, Phase 2 studies are being conducted for intermittent claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis,...
Investigational
Matched Description: … M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. ... Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis ... claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis, and …
Cimicoxib
Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.
Investigational
Matched Description: … Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and …
Displaying drugs 13926 - 13950 of 14706 in total